vs
Side-by-side financial comparison of MEDIFAST INC (MED) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $70.6M, roughly 1.1× Viridian Therapeutics, Inc.\DE). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-84.7M).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
MED vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | 69.4% | — |
| Operating Margin | -10.4% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | -36.9% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-1.64 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | — | ||
| Q3 25 | $89.4M | $70.6M | ||
| Q2 25 | $105.6M | — | ||
| Q1 25 | $115.7M | — | ||
| Q4 24 | $119.0M | — | ||
| Q3 24 | $140.2M | — | ||
| Q2 24 | $168.6M | — | ||
| Q1 24 | $174.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $-34.6M | ||
| Q2 25 | $2.5M | — | ||
| Q1 25 | $-772.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-8.2M | — | ||
| Q1 24 | $8.3M | — |
| Q4 25 | 69.4% | — | ||
| Q3 25 | 69.5% | — | ||
| Q2 25 | 72.6% | — | ||
| Q1 25 | 72.8% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 75.4% | — | ||
| Q2 24 | 73.2% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | -10.4% | — | ||
| Q3 25 | -4.6% | -56.7% | ||
| Q2 25 | -1.0% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | 4.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | -2.5% | -49.0% | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | -4.8% | — | ||
| Q1 24 | 4.8% | — |
| Q4 25 | $-1.64 | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $0.22 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $-0.75 | — | ||
| Q1 24 | $0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.9M | $503.0M |
| Total Assets | $248.0M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | — | ||
| Q3 25 | $173.5M | $490.9M | ||
| Q2 25 | $162.7M | — | ||
| Q1 25 | $164.6M | — | ||
| Q4 24 | $162.3M | — | ||
| Q3 24 | $170.0M | — | ||
| Q2 24 | $163.5M | — | ||
| Q1 24 | $156.4M | — |
| Q4 25 | $198.9M | — | ||
| Q3 25 | $214.7M | $503.0M | ||
| Q2 25 | $216.0M | — | ||
| Q1 25 | $211.0M | — | ||
| Q4 24 | $210.1M | — | ||
| Q3 24 | $207.3M | — | ||
| Q2 24 | $205.3M | — | ||
| Q1 24 | $211.0M | — |
| Q4 25 | $248.0M | — | ||
| Q3 25 | $268.2M | $577.1M | ||
| Q2 25 | $269.3M | — | ||
| Q1 25 | $280.0M | — | ||
| Q4 24 | $284.2M | — | ||
| Q3 24 | $291.2M | — | ||
| Q2 24 | $293.5M | — | ||
| Q1 24 | $302.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $-6.6M | $-84.7M |
| FCF MarginFCF / Revenue | -8.8% | -120.1% |
| Capex IntensityCapex / Revenue | 1.8% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.3M | — | ||
| Q3 25 | $12.1M | $-84.6M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $3.4M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $9.1M | — | ||
| Q2 24 | $13.1M | — | ||
| Q1 24 | $7.3M | — |
| Q4 25 | $-6.6M | — | ||
| Q3 25 | $10.8M | $-84.7M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $5.4M | — |
| Q4 25 | -8.8% | — | ||
| Q3 25 | 12.0% | -120.1% | ||
| Q2 25 | -4.5% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | -6.1% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 3.1% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | 0.2% | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.36× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
